Almirall profit quadruples in 2025 as dermatology fuels growth push - Invezz# Almirall profit quadruples in 2025 as dermatology fuels growth push[Earnings reports]Author[Noris Soto]Feb 23, 2026, 15:00 PM- Europe accounts for 91% of total sales; US revenue falls.- Dermatology drives 60% of revenue, led by Illumetri.- Almirall profit jumps 357% to €46.2M in 2025 on strong sales.Almirall, a pharmaceutical firm based in Spain, [ended 2025 with a net profit of €46.2 million], which was 357% more than its 2024 pr ...

US equities were little changed on Monday after President Donald Trump announced an increase in global tariffs to 15%, following a Supreme Court ruling that struck down his earlier "reciprocal†tariff framework. The S&P 500 hovered around the flatline during the session, while the Dow Jones Industrial Average and the Nasdaq Composite also traded with minimal movement. ...

Core Viewpoint - Eli Lilly is launching a multi-dose Zepbound KwikPen to enhance patient retention in the competitive GLP-1 market, aiming to simplify the user experience and streamline distribution logistics [1]. Group 1: Product Launch and Pricing - The new Zepbound KwikPen is designed to deliver four weekly doses of tirzepatide from a single device, replacing the traditional single-dose auto-injector format [1]. - The self-pay starter price for the KwikPen is set at $299 per month, marketed through LillyDirect to minimize cost surprises for patients [1]. - The multi-dose format has received FDA clearance, providing a regulatory basis for the launch beyond mere marketing [1]. Group 2: Strategic Rationale - Eli Lilly's strategy focuses on addressing "injection fatigue," which can lead to higher drop-off rates among patients using GLP-1 drugs for obesity and diabetes management [1]. - The launch of the monthly pen is seen as a retention tool to reduce the hassles associated with weekly injections, thereby encouraging consistent use [1]. - The company aims to control more of the patient journey, from prescribing to affordability, by implementing direct pricing strategies and partnerships to enhance accessibility [1].

Royal Bank of Canada stock double-tops ahead of Q1 earnings - Invezz# Royal Bank of Canada stock double- tops ahead of Q1 earnings[Finance & Banking]Author[Crispus Nyaga]Feb 23, 2026, 14:14 PM- The main catalyst for the stock this week will be its corporate earnings.- The daily chart shows that it has formed a double-top pattern.- Royal Bank of Canada's share price has been in a strong bull run for years.Royal Bank of Canada stock has been in an unstoppable bull run in the past few years and is now hovering ...

Merck creates separate oncology arm ahead of Keytruda patent loss - Invezz# Merck creates separate oncology arm ahead of Keytruda patent loss[Health & pharma]Author[Vatsala Gaur]Feb 23, 2026, 14:11 PM- Company banks on pipeline growth and recent acquisitions to offset pressure.- Leadership changes aim to prepare for Keytruda's 2028 patent expiry.- Merck splits its human-health business into oncology and specialty divisions.Merck said on Monday that it will split its human-health operations into two separate ...

We predicted the Blue Owl stock price crash to $10: what next for the private credit giant? - Invezz# We predicted Blue Owl stock price crash: what's next?[Finance & Banking]Author[Crispus Nyaga]Feb 23, 2026, 14:09 PM- The stock formed a head-and-shoulders pattern before this crash.- This plunge was in line with our previous forecast in November.- Blue Owl stock price has crashed from a record high of $25 to $10.Blue Owl stock price has crashed in the past few months, turning one of the most blue-chip finan ...

Core Viewpoint - Arcellx's stock surged approximately 80% following Gilead Sciences' announcement to acquire the cancer-therapy developer for $7.8 billion in an all-cash deal, with a definitive buyout price set at $115 per share [1]. Deal Structure - Gilead will pay $115 per share in cash, plus a contingent value right (CVR) worth an additional $5 per share if Arcellx's lead therapy, anito-cel, achieves at least $6 billion in cumulative global net sales by the end of 2029 [1]. - The total offer represents a premium of about 87% over Arcellx's previous closing price, prompting immediate trading activity towards the buyout price [1]. - The transaction is structured as a tender offer followed by a second-step merger, already approved by both companies' boards [1]. Strategic Importance - Gilead is acquiring anitocabtagene autoleucel (anito-cel), a CAR-T therapy for relapsed or refractory multiple myeloma, which presents a significant commercial opportunity despite intense competition from established products like Johnson & Johnson's Carvykti [1]. - Analysts have previously noted supportive data for anito-cel's potential, with comparisons to Carvykti as the datasets have matured [1]. - The FDA is expected to make a decision on anito-cel by December 23, 2026, which positions the acquisition within a near-launch timeframe rather than a distant research phase [1]. Historical Context - Gilead and Arcellx have collaborated in cell therapy since 2022, making this acquisition a consolidation of a program that Gilead is already familiar with [1].

In a sweeping and provocative macro-analysis titled "The 2028 Global Intelligence Crisis," Citrini Research has outlined a sobering vision of a financial future where the very success of Artificial In... ...

Core Insights - Domino's Pizza reported stronger-than-expected fourth-quarter US same-store sales, driven by aggressive promotions and new menu launches, which attracted budget-conscious diners [1] Company Performance - The company experienced a significant increase in same-store sales, indicating effective marketing strategies and product offerings [1] - The positive sales performance led to a rise in shares, reflecting investor confidence in the company's growth potential [1] Market Trends - The success of Domino's promotions and menu innovations highlights a trend where consumers are seeking value, particularly in the current economic climate [1] - The competitive landscape in the fast-food industry is intensifying, with companies needing to adapt to changing consumer preferences and economic pressures [1]

US stock index futures declined on Monday as investors reacted to renewed tariff uncertainty after US President Donald Trump announced a new 15% global duty, even after a Supreme Court ruling struck down most of his earlier levies. The Supreme Court, in a 6–3 decision on Friday, voided a large portion of tariffs imposed last year, finding the emergency law used by the administration did not authorize such measures. ...